Recruiting studies: Estrogen Receptor Low Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226 [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
Phase 2 · 1 location(s) · Asan Medical Center · NCT07314073 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic
Phase 3 · 72 location(s) · National Cancer Institute (NCI) · NCT07391774 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT02476786 SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Phase 2 · 6 location(s) · Kathy Miller · NCT05846789 OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Phase 4 · 2 location(s) · Gangnam Severance Hospital · NCT05333328 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High
Phase 3 · 555 location(s) · Stemline Therapeutics, Inc. · NCT06492616

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.